ODN M362 是一种 TLR9 激动剂,可作为疫苗佐剂,能激活小鼠脾细胞,诱导人肝癌细胞凋亡 (apoptosis),上调人肝癌细胞中的炎性细胞因子并抑制其增殖,同时上调 TLR9/TLR6 表达,通过 IRAK4 和 IRF7 激活下游信号通路,强烈放大抗原特异性的细胞免疫应答从而参与固有免疫激活,可用于肝细胞癌和乳腺癌的相关研究。
产品编号: MS-S85388 纯度: 96.01% CAS No.: 934655-87-5 分子量: 8049.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

ODN M362 是一种 TLR9 激动剂,可作为疫苗佐剂,能激活小鼠脾细胞,诱导人肝癌细胞凋亡 (apoptosis),上调人肝癌细胞中的炎性细胞因子并抑制其增殖,同时上调 TLR9/TLR6 表达,通过 IRAK4 和 IRF7 激活下游信号通路,强烈放大抗原特异性的细胞免疫应答从而参与固有免疫激活,可用于肝细胞癌和乳腺癌的相关研究。

生物实验数据

生物活性 ODN M362 is a TLR9 agonist that serves as a vaccine adjuvant, activating mouse splenocytes, inducing apoptosis in human hepatoma cells, upregulating inflammatory cytokines and inhibiting proliferation in human hepatoma cells, and upregulating TLR9/TLR6 expression to activate downstream signaling pathways through IRAK4 and IRF7, thereby strongly amplifying antigen-specific cellular immune responses and participating in innate immune activation, and it can be used for research on hepatocellular carcinoma and breast cancer.
IC50 & Target

TLR9

 

TLR6

 

体外研究
(In Vitro)

ODN M362 (0.25-4 μg/mL; 24-72 h) 可强效抑制人肝癌细胞 HepG2 和 H7402 的增殖。
ODN M362 (0.5 μg/mL; 24 h) 不影响人肝癌细胞 H7402 的细胞周期分布。
ODN M362 (0.5-2 μg/mL; 24 h) 以剂量依赖方式诱导人肝癌 H7402 细胞发生凋亡,在 2 μg/mL 作用 24 h 时的凋亡率为 32.73%。
ODN M362 (0.5 μg/mL; 24 h) 可显著增加人肝癌 H7402 细胞中 TUNEL 阳性的凋亡细胞数量。
ODN M362 (0.5 μg/mL; 24 h) 可诱导人肝癌细胞 H7402 发生凋亡,该效应依赖于其硫代磷酸化修饰。
ODN M362 (0.5 μg/mL; 24 h) 可在人肝癌 H7402 细胞中使 TLR9 mRNA 上调 8~10 倍,并增加炎症细胞因子 mRNA (IFN-α、IFN-β、TNF-α、IL-6、IL-8) 的表达。
ODN M362 (0.5 μg/mL; 48 h) 可独立于 TLR9 激活诱导人肝癌细胞 H7402 发生凋亡。
ODN M362 (10 μM) 可作为佐剂增强来自 HLA-A2+ 供体的初始 CD8+ T 细胞的 MamA2.1 特异性活化,在效应细胞与靶细胞比例为 40:1 时,诱导产生 12.6% 的四聚体阳性细胞,并对 AU565 (HLA-A2+/MamA+) 乳腺癌细胞产生 76% 的特异性裂解。
ODN M362 (10 μM; 5 h) 可在 THP-1 细胞中诱导显著的形态及颗粒度变化,单独处理时,有 32.19% 的细胞同时表现出体积增大和颗粒度增加的特征。
ODN M362 (10 μM; 5 h) 与 MamA2.1 肽联合给药时,可增强 THP-1 细胞中成熟标志物和吞噬标志物的表达,诱导树突状细胞样分化。
ODN M362 (10 μM; 5 h) 与 MamA2.1 肽联合给药时,可显著增强 THP-1 细胞中免疫刺激性细胞因子、趋化因子及效应细胞因子的产生。
ODN M362 (10 μM; 5 h) 可上调 THP-1 细胞中 TLR-9 和 TLR-6 的 mRNA 及蛋白表达,且与 MamA2.1 肽联合给药时,能通过 IRAK4、IRF7 和 IRF5 增强下游信号通路。
ODN M362 介导的 THP-1 细胞功能增强及后续 CD8+ T 细胞活化依赖于 TLR-9 与 TLR-6 的协同信号通路,敲低其中任意一种受体都会降低 IL-12p70 的分泌、树突状细胞标志物的表达以及 MamA 特异性 CD8+ T 细胞应答。

Cell Cycle Analysis

Cell Line: human hepatocellular carcinoma H7402 cell line
Concentration: 0.5 μg/mL
Incubation Time: 24 h
Result: Did not alter the cell cycle distribution relative to controls.

Apoptosis Analysis

Cell Line: human hepatocellular carcinoma H7402 cell line
Concentration: 0.5, 1 and 2 μg/mL
Incubation Time: 24 h
Result: Induced an apoptotic rate of 27.96% at 0.5 μg/mL.
Induced an apoptotic rate of 23.66% at 1 μg/mL.
Induced an apoptotic rate of 32.73% at 2 μg/mL.

Apoptosis Analysis

Cell Line: human hepatocellular carcinoma H7402 cell line
Concentration: 0.5 μg/mL
Incubation Time: 24 h
Result: Significantly increased the number of TUNEL immunopositive cells relative to controls.\nInduced an apoptotic rate of 24.31%, while the non-phosphorothioate-modified ODN 2006-G5 did not induce significant apoptosis.

Real Time qPCR

Cell Line: human hepatocellular carcinoma H7402 cell line
Concentration: 0.5 μg/mL
Incubation Time: 24 h
Result: Upregulated TLR9 mRNA expression by 8-10 fold relative to controls.
Upregulated IFN-α, IFN-β, TNF-α, IL-6, and IL-8 mRNA expression, with IFN-α levels significantly higher than in ODN M362 Ctrl-treated cells.

Western Blot Analysis

Cell Line: human hepatocellular carcinoma H7402 cell line
Concentration: 0.5 μg/mL
Incubation Time: 30 min, 60 min
Result: Did not induce a noticeable change in phosphorylated NF-κB expression relative to controls, unlike LPS stimulation.

Apoptosis Analysis

Cell Line: human hepatocellular carcinoma H7402 cell line
Concentration: 0.5 μg/mL
Incubation Time: 24 h (following 24 h pre-incubation with TLR9 siRNA)
Result: Induced apoptosis at a rate comparable to non-pretreated cells, with silencing of TLR9 expression not reducing the apoptotic effect.

Cell Cytotoxicity Assay

Cell Line: Naïve CD8+ T cells from healthy HLA-A2+ human donors, THP-1 (HLA-A2+), AU565 (HLA-A2+/MamA+), MCF7 (HLA-A2+/MamA−)
Concentration: 10 μM (THP-1 cell pre-treatment)
Incubation Time: 5 h (THP-1 pre-treatment); 5 days (CD8+ T cell stimulation); 48 h (cytotoxicity incubation)
Result: Induced MamA2.1 tetramer staining of 12.6% in activated CD8+ T cells.
Induced 76% specific lysis of AU565 breast cancer cells at an effector-to-target ratio of 40:1.
Significantly enhanced expression of TNFα, IFNγ, and granzyme B in activated CD8+ T cells.
Did not induce significant cytotoxicity on MamA-negative MCF7 (HLA-A2+/MamA−) breast cancer cells.

Cell Differentiation Assay

Cell Line: THP-1
Concentration: 10 μM
Incubation Time: 5 h
Result: Induced 32.19% of THP-1 cells to show enhanced forward scatter and side scatter (FSC/SSC-Q3 quadrant).
Induced 34.85% of THP-1 cells to show enhanced forward scatter only (FSC-Q2 quadrant).
Co-treatment with MamA2.1 peptide induced 31.71% of THP-1 cells to show enhanced FSC and SSC, and 30.04% to show enhanced FSC only.
体内研究
(In Vivo)

ODN M362 (5.0 μg/mL;瘤内注射;每 4 天 1 次;共 40 天) 可使无胸腺裸鼠的皮下人肝细胞癌肿瘤生长抑制 46.9%,且未观察到其对脾脏或肝脏相对体重的重量产生影响。
ODN M362 (100 μg/只小鼠;腹腔注射;每 2 周 1 次,共 4 次) 可作为 MamA2.1 肽疫苗的强效佐剂,增强 MamA 特异性 CD8+ T 细胞的活化,并在第 45 天时将 SCID/beige 小鼠的原位 AU565 乳腺癌肿瘤体积降至 100 mm3 以下。

Animal Model: athymic (nude-nude) (5-week-old, female, subcutaneous inoculation with 1×107 H7402 human hepatocellular carcinoma cells)
Dosage: 5.0 μg in 100 μL
Administration: intratumoral injection; every 4 days; day 15 to day 55
Result: Inhibited tumor growth by 46.9% compared to control groups.
Did not affect the ratio of spleen weight to body weight or the ratio of liver weight to body weight.
Animal Model: HLA-A2+/C57Bl/6 transgenic mice; SCID/beige mice (breast cancer orthotopic implantation model)
Dosage: 100 μg/mouse
Administration: intraperitoneally; 4 doses at 2-week intervals
Result: Enhanced IL-12p70 mRNA expression, TLR-9 mRNA expression, and TLR-6 mRNA expression in peritoneal macrophages compared to peptide-only vaccinated mice.
Achieved ~19% MamA2.1 tetramer staining of CD8+ T cells, significantly higher than the ~7% staining in peptide-only vaccinated mice.
Reduced mean tumor volume to <100 mm3 at day 45 post-tumor implantation, compared to ~250 mm3 in mice receiving CD8+ T cells from peptide-only vaccinated mice.
性状 固体
颜色 White to off-white

化学信息

分子量 8049.50
CAS No. 934655-87-5

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (12.42 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM0.1242 mL0.6212 mL1.2423 mL3.1058 mL
5 mM0.0248 mL0.1242 mL0.2485 mL0.6212 mL
10 mM0.0124 mL0.0621 mL0.1242 mL0.3106 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础